Prognostic value of baseline FDG PET/CT in HER2-positive metastatic breast cancer treated with first-line trastuzumab, pertuzumab, and docetaxel.

Breast Cancer Res · 2025 · PMC12866219 · PMID 41372775

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

0) and the presence of lung metastases were associated with numerically lower odds of durable response (OR 0.57; 95% CI 0.27–1.20 and OR 0.49; 95% CI 0.21–1.14, respectively), these associations did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.